4D Molecular Therapeutics... (FDMT)
4.41
-0.12 (-2.65%)
At close: Mar 03, 2025, 12:21 PM
4D Molecular Therapeutics Income Statement
Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
Revenue | n/a | 20.72M | 3.13M | 18.04M | 13.61M | 6.99M | 14.13M | 5.79M |
Cost of Revenue | n/a | 97.1M | 3.88M | 3.02M | 53.04M | 38.72M | 18.36M | 13.57M |
Gross Profit | n/a | -76.37M | -751K | 15.02M | -39.43M | -31.73M | -4.23M | -7.78M |
Operating Income | -187.84M | -112.87M | -110.03M | -71.33M | -56.66M | -50.76M | -10.4M | -11.27M |
Interest Income | 27.05M | 12.21M | 2.57M | 137K | 152K | 1.5M | 850K | 89K |
Pretax Income | -160.87M | -100.84M | -107.49M | -71.32M | -56.69M | -49.31M | -9.55M | -11.22M |
Net Income | -160.87M | -100.84M | -101.08M | -68.3M | -56.54M | -52.94M | -9.55M | -11.22M |
Selling & General & Admin | 46.58M | 36.49M | 32.91M | 28.01M | 17.24M | 13.89M | 6.17M | 3.49M |
Research & Development | 141.3M | 97.1M | 80.25M | 61.36M | 53.04M | 38.72M | 18.36M | 13.57M |
Other Expenses | n/a | n/a | 2.54M | 16K | -181K | -46K | -2K | -40K |
Operating Expenses | 187.88M | 133.59M | 113.16M | 89.37M | 70.28M | 52.61M | 24.53M | 17.06M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 133.59M | 113.16M | 89.37M | 70.28M | 52.61M | 24.53M | 17.06M |
Income Tax | n/a | n/a | -6.42M | -3.02M | -152K | 3.63M | 848K | -89K |
Shares Outstanding (Basic) | 53.94M | 39.13M | 32.35M | 27.73M | 26.68M | 26.49M | 12.52M | 14.84M |
Shares Outstanding (Diluted) | 53.94M | 39.13M | 32.35M | 27.73M | 26.68M | 26.49M | 12.52M | 14.84M |
EPS (Basic) | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
EPS (Diluted) | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2 | -0.76 | -0.76 |
EBITDA | -187.84M | -107.12M | -106.15M | -68.31M | -55.22M | -44.62M | -9.7M | -10.65M |
Depreciation & Amortization | n/a | 5.75M | 3.88M | 3.02M | 1.44M | 1M | 697K | 626K |